Micro rna
Upcoming SlideShare
Loading in...5
×
 

Micro rna

on

  • 95 views

Role of miRNA in host-virus interaction: current insights and future perspectives

Role of miRNA in host-virus interaction: current insights and future perspectives

Statistics

Views

Total Views
95
Views on SlideShare
95
Embed Views
0

Actions

Likes
0
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • First discovered in 1993 by Victor Ambros at Harvard (lin-4) <br /> Let-7 discovered in 2000 by Frank Slack as a postdoc at Harvard (Ruvkun lab) <br />
  • Drosha and Pasha are part of the “Microprocessor” protein complex (~600-650kDa) <br /> Drosha and Dicer are RNase III enzymes <br /> Pasha is a dsRNA binding protein <br /> Exportin 5 is a member of the karyopherin nucleocytoplasmic transport factors that requires Ran and GTP <br /> Argonautes are RNase H enzymes <br />
  • Figure I. Model of miRNA target accessibility. In addition to the well-described importance of sequence matching of particular residues (nt 2–7) in the 5 <br /> 0 <br /> end of miRNAs <br /> with mRNA targets, we propose that miRNAs can access their target sites only when they are physically accessible. Binding energy and secondary structure of the RNA, <br /> which itself could be regulated, might promote or inhibit miRNA–mRNA interactions. For example, despite a high degree of sequence matching to a region of the mRNA <br /> that forms a stem–loop or hairpin, a miRNA might not be able to access its binding site and, thus, would be unable to repress translation.
  • Figure 2. Location of miRNA genes within herpesvirus genomes. Genomes are represented for alphaherpesviruses (HSV-1, HSV-2, MDV-1, MDV-2), a betaherpesvirus <br /> (HCMV), and gammaherpesviruses (EBV, LCV, RRV, KSHV, MHV-68). MDV-1 and MDV-2 are drawn as one complete genome with the respective miRNA coding regions <br /> depicted in more detail. Genomes are not drawn to scale. The figure was compiled from data published in Refs.[14,16,22–24,27,31,33,34,36,37]. Abbreviations: US, unique <br /> short; UL, unique long; LAT, latency associated transcript.
  • JCV <br /> BKV <br /> muPyV
  • Figure 2. Mechanisms implicated in miR-122 mediated increase in HCV RNA abundance. <br /> MicroRNA (miRNA)-122 binds at two sites within the 5’UTR of the HCV RNA forming a <br /> unique miRNA-viral RNA complex characterized by 3’ overhang and internal bulge <br /> within the miRNA molecules. The 3’ overhang of miR-122 at the first site is proposed to <br /> mask the 5’ end of the HCV RNA and to increase its cytoplasmic stability by preventing <br /> its recognition by cytoplasmic RNA sensors such as the retinoic acid-inducible gene-I <br /> (RIG-I) as well as nucleolytic digestion by 5’ exonucleases. Additionally, binding of <br /> miR-122 to the HCV RNA stimulates virus release and viral RNA translation by <br /> enhancing the association of the 48S translation initiation complex.
  • Figure 1: The microRNA (miRNA)-virus vaccine strategy. <br /> In 2009, a group of researchers from Mount Sinai School of Medicine found that using microRNA response elements (MREs) can supplement the effectiveness of LAIVs. <br /> Viral replication can be regulated in a tissue-specific manner by incorporating miRNA target sites into the viral genome. In cells that express the miRNA (e.g., brain, top cell), the miRNAs are processed and transported to the cytoplasm, where they mediate cleavage of viral RNA. Viral replication is restricted to cells in which the miRNA is not expressed (e.g., intestine, bottom cell). The engineered virus can therefore trigger a natural immune response in target tissues without the associated risk of dissemination and disease.

Micro rna Micro rna Presentation Transcript

  • Major Credit Seminar Adil Anamul Haq PhD Scholar Division of Virology, IVRI Mukteswar Welcome Role of miRNA in host-virus interaction: current insights and future perspectives
  •  Introduction  Biogenesis  Viral miRNAs  Cellular miRNAs  Applications  Summary  Future Perspectives Contents
  • What are miRNAs?  Non-coding RNAs ~22nts in length  Post-transcriptionally regulate gene expression  Regulate ~60% protein coding genes (Friedman et al., 2009)  Encoded both by hosts and viruses  Important effects in  Signaling pathway  Metabolism  Apoptosis  Cell proliferation  Regeneration  Stem cell division  Oncogenesis  Nervous system control  Developmental timing  Hematopoietic cell fate  Regulation of Immune system (Libri et al., 2008) miRNA mRNA
  • Victor R. Ambros Historical Background  1993: lin-4 in C. elegans (Lee et al., 1993)  Thought to be an oddity of nematodes  No other miRNAs found for next 7 years !!!  Second miRNA – let-7 in C. elegans (Reinhart et al.,2000)  Let-7 found 100% conserved in genomes of mice and humans (Pasquinelli et al., 2000)  Three landmark papers in Science 1. Lagos-Quintana et al., 2001; 2. Lau et al., 2001 3. Lee and Ambros, 2001 C. elegans
  • Historical Background Sébastien Pfeffer  First reported by Thomas Tuschl and colleagues (Pfeffer et al., 2004)  First v-miRNA seen in EBV  Most not conserved between viruses  Presently > 250 viral miRNAs are known (Cullen et al., 2013)
  • Canonical miRNA biogenesis pathways (Sonkoly and Pivarcsi, 2009)
  • Non-canonical miRNA biogenesis pathways Two pathways:  Drosha- independent  MHV68  BLV  Dicer- independent  miR-451 (Libri et al., 2013)
  • miRNAs mRNA Cleavage Translational Repression Fate of mRNA Boss et al., 2011
  • ‘Seed’ Sequence (Zhao and Srivastava, 2007)  6-7 nt signature region at 5’ end (Bartel, 2009)  Hexamer = 2-7 nt  Heptamer = 2-8 nt  Directs miRISC to target 3’ UTR of mRNA Plant miRNAs differ in that they are entirely complementary to their target genes
  • miRNA in host-viral Interaction
  • Which viruses encode miRNA ? Herpesviruses code for ~ 90% of known miRNAs (Cullen, 2013)  Herpesviridae  Polyomaviridae  Ascoviridae  Baculoviridae  Iridoviridae  Adenoviridae  Most recently Retroviridae Based on the requirements of nuclear machinery and RNA cleavage for miRNA processing, it is no surprise that cytoplasmic replicating DNA viruses and RNA viruses have not been found to express miRNAs (Boss et al., 2011)
  • Family/Sub-family Species Host Pre-miR Hairpins Mature miRs α-Herpesviruses Herpes Simplex Virus-1 Human 16 25 Herpes Simplex Virus-2 Human 18 24 Herpes B virus Human 3 3 Herpesvirus of turkey Turkey 17 28 Bovine herpesvirus 1 Bovine 10 12 Pseudorabies virus Swine 13 13 Marek’s disease virus -1 Chicken 14 26 Marek’s disease virus -2 Chicken 18 36 Β-Herpesviruses Human cytomegalovirus Human 11 17 Mouse Cytomegalovirus Murine 18 28 Human herpesvirus 6B Human 4 8 γ-Herpesviruses Kaposi’s sarcoma associated herpes virus Human 12 25 Epstein-Barr Virus Human 25 44 Rhesus Lymphocryptovirus Simian 36 50 Rhesus Monkey Rhadinovirus Simian 15 25 Mouse Gamma Herpesvirus 68 Murine 15 28 Herpesvirus Saimiri strain A11 Simian 3 6 List of Viral encoded miRNAs
  • Family/Sub- family Species Host Pre-miR Hairpins Mature miRs Polyomaviruses Simian Virus 40 Simian 1 2 BK Polyomavirus Human 1 2 JC Polyomavirus Human 1 2 Mouse polyomavirus Mouse 1 2 Merkel cell polyomavirus Human 1 2 SA12 Simian 1 2 RETROVIRUS Bovine Leukemia virus Bovine 5 8 Iridoviridae Singapore Grouper Iridovirus Fish 14 15 Ascoviridae Heliothis virescens ascovirus Insect 1 1 Baculoviridae Bombyx mori nucleopolyhedrosis virus Insect 4 4 Adenoviridae Human adenoviruses types 2 and 5 (others likely) Human 2 3 Unclassified Bandicoot papillomatosis carcinomatosis virus type 1 Bandicoots (marsupial) 1 1 Bandicoot papillomatosis carcinomatosis virus type 2 Bandicoots (marsupial) 1 1 (Kinkaid & Sullivan, 2012)
  • Location of miRNA genes within herpesvirus genomes Boss et al., 2009
  • Strategies for determining viral-encoded miRNA function  Bottom-up Approach  Top-down Approach Grundhoff and Sullivan, 2011
  • Functions of viral encoded miRNAs Grouped into two classes:  Analogs of host miRNAs  Specific to viruses  Regulation of latency/persistency  Prevention of apoptosis  Alteration of cell cycle  Viral immune evasion  Transformation  Autoregulation of virus gene expression (Grundhoff & Sullivan, 2011) Gottwein & Collen, 2008
  • Regulation of latency/persistency The role of virus-encoded miRNAs in promoting KSHV latency (Grundhoff & Sullivan, 2011) KSHV miR-K12-5p Rbl2 Increase in DNA methylation First reported evidence that viral miRNAs can directly impact the epigenetic status of herpesvirus genomes during latency (Lu et al., 2010)
  • Evading the Immune Response Direct Regulation Autoregulation KSHV miR—K12-3 KSHV miR—K12-7 LIP Secretion IL-6 & IL-10 (Quin et al., 2010) (Boss & Renne, 2011)
  • Autoregulation miR—S1- 5p miR-S1-3p T- Antigen CTL Response (Sullivan et al., 2005) JCV BKV muPyV This study provided the first evidence that viral miRNAs can inhibit CTL recognition by directly targeting viral antigens (Boss et al., 2011) T- Antigen SV40: miRNAs encoded antisense to the T-antigen that mediate its transcript cleavage during infection (Sullivan et al., 2005)
  • Evading the Immune Response HCMV miR- Ul112-1 KSHV miR-K12-7 MICB NK Cell & CTL Response EBV miR-BART2- 5p NKG2D-R (Stern-Ginossar et al., 2007; Thomas et al., 2008) HCMV-, EBV-, and KSHV-encoded miRNAs target the MICB gene by completely different sequences raises a very interesting question about the co-evolution of viral miRNAs and their corresponding cellular targets (Boss et al., 2011) (Boss & Renne, 2011)
  • Preventing Apoptosis EBV miR-BART5 rLCV miR-BART5 PUMA Block Apoptosis (Choy et al., 2008) Repress RNAhybrid miRANDA Predicted target of EBV miR- BART5 It represents the conservation of miRNAs from different viruses (Choy et al., 2008)
  • Alteration of cell cycle HCMV miR-US25-1:  ~ 15 targets identified  Most targets in cell cycle  Cyclin E2 is one of the targets (Grey et al., 2010) This is the first report of a virus miRNA targeting the 5′UTR of an mRNA (Grey et al., 2010) (Grey et al., 2010)
  • Transformation 12 KSHV miRNAs Thrombospondin Angiogenesis anti-angiogenic factor frequently mutated in various cancers KSHV (Samols et al., 2007)
  • Viral miRNA mimicking a host miRNA  Known as ‘analogs’  Three Viruses known to encode:  KSHV  MDV1  BLV (Kincaid & Sullivan, 2012) Mimicking host miRNAs provides obvious benefits to a virus by allowing it to access a pre-existing target network of numerous host transcripts that may have been selected for a particular functional outcome (e.g., prevention of apoptosis or evasion of immune signaling) (Kincaid & Sullivan, 2012)
  • miR-155 mimics—viral analogues of a human oncomir? Kincaid & Sullivan, 2012  miR-155 originally identified as product of bic gene (Clurman and Hayward, 1989)  Expressed in  many lymphomas  acute myeloid leukemia (AML)  solid tumors of the breast, colon and lung  Represents an “oncomiR” miR-155 KSHV miR-K11 MDV1 miR-M4 Strikingly, although the lymphotropic EBV does not encode a miR-155 mimic of its own, the viral LMP-1 protein strongly induces expression of the cellular miR-155 in latently infected B-cells (Gatto et al., 2008)
  • Potential effects of cellular miRNAs on Viral replication (Gottwein & Collen., 2008)
  • Antiviral miRNAs HIV-1 PFV-1 Influenza VSV - 5-human encoded miRNAs - target nef, vpr, vif, vpu (Hariharan et al. , 2005) - miR-24 & miR-93 - Restrict replication (Otsuka et al. , 2007) - miR-32 - Restrict replication (Lecellier et al. , 2005) - hsa-miR-507&136 - target PB2 & HA. - (Scaria et al., 2007) Cellular miRNAs as Antivirals
  • miR-122: Cellular miRNA enhancing Viral Replication (Gupta et al., 2012)
  • Attenuated vaccines Oncolytic Virotherapy Determination of Cell Tropism Antiviral Drug Development Applications
  • MIRA (MicroRNA Attenuation) Technology miRNA-controlled viruses showed no evidence of pathogenesis, but their limited replication made them ideal vaccine candidates (Barnes et al., 2008) Poliovirus
  • Live attenuated IAV vaccine  Incorporated MRE  miR-93 (a ubiquitous miRNA)  ORF of influenza A nucleoprotein coding regions  H1N1 (Perez et al., 2009) (Perez et al., 2009)
  • Engineering microRNA responsiveness for Oncolytic Virotherapy Colorectal Carcinoma  Measles Virus (Leber et al., 2011)  VSV (Edge et al., 2008)
  • Engineering microRNA to determine cell specificity for viruses Determine role of haematopoietic cell in viral replication?  DENV strain engineered to encode four HPC- specific miR-142- targeting sites in the 3ʹ UTR of the virus  miR-142 completely blocked spread of the infection in vivo, suggesting that replication in haematopoietic cells is required for viral dissemination
  • Janssen et al., 2013 Miravirsen is a LNA modified phosphorothiolate antisense oligonucleotide targeting and blocking miR-122
  • Miravirsen- the 1st miRNA targeted drug  First drug to exploit miRNA for therapeutic use  As a host targeting agent miravirsen poses a high barrier to resistance  Can work in all HCV genotypes because miR-122 binding sites are conserved  Has successfully completed Phase II clinical trial (Janssen et al., 2013)
  • Summary  MicroRNAs are short 22 nt ncRNAs  MicroRNAs are involved in post transcriptional gene regulation  Encoded both by viruses and hosts  Degree of complementarity between a miRNA & its target determine the regulatory mechanism  With notable exceptions, there is a striking lack of evolutionary conservation of most viral miRNAs  Have been used for therapeutic purpose  As new discoveries in viral miRNA function are made new questions emerge, making the complexities governing viral-host interactions, at the least, a little more transparent (Boss et al., 2011)
  • Future Perspectives  Understand why some members of the same virus subfamilies do and do not encode miRNAs (e.g., HTLV in the Delta Retroviridae or VZV in the alpha herpesviruses  How do viral miRNAs work synergistically with viral proteins to regulate the viral replication cycle?  Strategies to develop new therapeutic interventions  Viral miRNA target identification  Relevant in vivo model systems for viral miRNAs that recapitulate all modes of infection